Strategies for Accelerating Preclinical Development of Vaccines and Therapeutic Proteins
Tuesday, August 20, 2013 from 1:00 PM to 6:00 PM (EDT)
Expression of an Antigen Targeting Fusion Protein
Mark Poznansky, MD, PhD, Director of the Vaccine & Immunotherapy Center at Massachusetts General Hospital
Expression of a self assembling immune adjuvant and antigen targeting fusion protein to accelerate the development of new vaccines for emerging infectious diseases. Dr. Mark Poznansky will present on the work currently underway in his group at the Massachusetts General Hospital Vaccine and Immunotherapy Center on the newly formed VaxCelerate consortium.
Development of Protein Capsular Matrix Vaccine (PCMV) Technology
Kevin P. Killeen, PhD, Chief Scientific Officer, Matrivax Research and Development Corporation, Boston, MA
Matrivax R&D Corp. is a start-up biotechnology company with R&D operations located in Boston, USA and a GMP vaccine pilot facility in Haikou, China. We are developing a proprietary vaccine process, termed Protein Capsular Matrix Vaccine (PCMV), which entraps polysaccharides in a cross-linked protein ‘carrier’ or matrix. Matrivax is researching and developing pneumococcal and enteric fever (Typhoid) PCMV candidates. Preclinical data and typhoid fever PCMV GMP manufacture and Phase 1 clinical trial plans will be discussed.
Finding the perfect match for your protein: a comparison of host systems for heterologous protein expression
Dominic Esposito, Ph.D. Director, Protein Expression Laboratory Advanced Technology Program at SAIC-Frederick, Inc.
Many host platforms are available for high-level heterologous protein production including bacterial, insect, yeast, and mammalian systems. It is often difficult to predetermine the best system for a given protein, but a clearer understanding of the benefits and drawbacks of the different hosts along with robust parallel production screening processes can improve the odds and reduce time and cost to purified protein
Quality Considerations in Early BioPharma Development
Sheila G. Magil, Sr. Consultant at BioProcess Technology Consultants, Inc.
Many decisions made early in development of a biopharmaceutical significantly impact the quality of the final product. Quality input should not be limited to those activities which are cGMP activities. Rather, quality considerations are needed throughout early development from cell line/strain development through final analytical and process qualification. This presentation will discuss how decisions made early in development of a protein, for example selection of the most appropriate cell line or strain, profoundly affect the overall development program.
Technology Transfer, Scale Up and Factors to Consider when Progressing from Discovery to Clinic with your Therapeutic Protein
Cynthia Wooge, Ph.D., Global Strategic Marketing, SAFC
Effective introduction of a therapeutic protein or protein conjugate into clinical trials requires not only an appropriate target molecule, but also a defined path towards efficient, robust manufacturing with suitable quality parameters. Considerations for taking a bench scale process into a production setting will be discussed, as well as what to expect and what to avoid during the technology transfer and scale up stages.
Cocktail Reception Hosted By SAFC and Boehringer Ingelheim: 5-6pm
When & Where
Pfenex Strain Engineering
Pfenex Strain Engineering, a division of Pfenex Inc., leverages its cutting edge technology platform and provides strain engineering services for those companies developing therapeutics and vaccines and for those researchers seeking reagents for research use. For more information, please visit www.pfenex.com